- Home
- / Esperion Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Esperion Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.1
2024-10-29
Market Capitalization
$416 M
2024-10-29
Revenue
$403.1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 78.4M | 75.5M | 116.3M | 332.3M | 403.1M |
| Cost of goods sold | 14.2M | 27.0M | 43.3M | ||
| Gross profit | 64.2M | 48.5M | 73.1M | ||
| Gross profit margin, % | 81.9% | 64.3% | 62.8% | ||
| General and administrative expense | 185.0M | 109.1M | 142.5M | 163.1M | 165.8M |
| Operating expense total | 291.0M | 228.0M | 228.6M | 303.4M | 213.6M |
| EBIT | (226.7M) | (179.5M) | (155.6M) | 54.4M | 60.3M |
| EBIT margin, % | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Interest expense | 46.4M | 56.8M | 59.0M | ||
| Pre tax profit | (20.8M) | ||||
| Income tax expense | 1.8M | ||||
| Net Income | (269.1M) | (233.7M) | (209.2M) | (51.7M) | (22.7M) |
| EPS | (9.3) | (3.5) | (2.0) | (0.3) | (0.1) |